Applications are invited for a research assistant to join a highly motivated stem and progenitor cell team working under the direct supervision of Professors Paul Riley and Roger Patient. The project is funded by OxStem Cardio, the fourth stand-alone company to be formed under the OxStem umbrella (www.oxstem.co.uk). OxStem is a revolutionary spin-out company from the University of Oxford, founded by Professor Steve Davies, Professor Dame Kay Davies and Professor Angela Russell, which recently raised a record-breaking £16.9M in its initial funding round. The company is a developer of cell programming therapies with a unique approach to regenerative medicine, aiming to develop small molecules that can activate repair mechanisms that already exist within the body. OxStem is leading the field into a new era of small molecule-driven stem and stem-like cell reprogramming that will be transformative for healthcare.
OxStem Cardio aims to identify new classes of drug candidates that will activate epicardium-derived progenitor cells to promote cardiovascular regeneration. The team will focus initially on restoring lost functional tissue after myocardial infarctions, with a parallel focus on modulating oedema and inflammation by stimulating coronary lymphatic vessels. This is an extraordinary opportunity to work with world leading researchers and contribute to the development of innovative new therapies for areas of significant unmet medical need.
This project is a collaboration between the Departments of Chemistry, Physiology Anatomy and Genetics, and the Weatherall Institute of Molecular Medicine including Professor Angela Russell, Professor Steve Davies, Professor Paul Riley and Professor Roger Patient.
The postholder will contribute to in vitro high throughput screening assays, using human patient-derived primary cells and human embryonic stem-cell derived cell models focusing on epicardium-derived progenitors and the lymphatic vasculature, and facilitate assays for secondary screens and validation of targets, to include testing in relevant animal models (zebrafish and medaka) to progress towards drug discovery.
Candidates must have a first degree in a relevant field. Expertise in molecular biology techniques, cell culture and imaging with experience of animal models including husbandry and small animal surgery is preferable.
You will be based across two sites: the Sherrington Building, South Parks Road, Oxford, OX1 3PT and The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS.
The position is fixed-term until 16 November 2019. An early start date is preferable.
The closing date for applications is 12.00 midday on 30 September 2017.
Please note that the University of Oxford's retirement policy is changing. With effect from October 1 2017, all employees at Grade 8 and above will have a retirement age of 68, and all employees at Grades 6 and 7 will no longer have a set retirement age. Further details are available at: www.ox.ac.uk/about/jobs/preemploymentscreening